Last reviewed · How we verify
NCT05853159
Clinical and Radiological Prognostic Factors of Acute Necrotizing Encephalopathy in Sohag University Hospital
trial testing Basic Laboratory investigations , Cerebrospinal fluid analysis in Acute Necrotizing Encephalopathy in 25 participants. Status unknown.
1 May 2024
Quick facts
| Lead sponsor | Sohag University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 1 May 2023 |
| Primary completion | 1 May 2024 |
| Estimated completion | 1 May 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Basic Laboratory investigations , Cerebrospinal fluid analysis
Conditions studied
- Acute Necrotizing Encephalopathy — all drugs for Acute Necrotizing Encephalopathy →
Sponsor
Sohag University
Who can join
Adults 2 Months to 12, any sex, with Acute Necrotizing Encephalopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute necrotizing encephalopathy of childhood (ANEC) is a fulminant type of encephalopathy. Most reported cases occur in Asian children with the highest prevalence among patients between the age of 6 and 18 months. The most common clinical presentations are fever, rapid alteration in the level of consciousness, and seizures, in addition to characteristic findings in brain imaging that include, but are not limited to, bilateral thalamic lesions with supra and infra-tentorial lesions of variable dimensions. The diagnosis of ANEC was determined by specific diagnostic criteria as described by Mizuguchi \[1\] which consist of 1. Encephalopathy preceded by viral febrile illness with rapid deterioration in the level of consciousness and convulsions. 2. Absent cerebrospinal fluid (CSF) pleocytosis. 3. Symmetric multifocal brain lesions. 4. Elevation in serum aminotransferase levels. 5. Exclusion of similar diseases. The ANE severity score was used to assess the severity of illness after admission for shock (3 points), brainstem lesions (2 points), age \>4 years (2 points), platelet (PLT) count \< 100,000 (1 point), and elevated CSF protein (1 point) was observed. \[3\] A total score of 9
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05853159
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Sohag University trials
Trials by the same sponsor.
- NCT07119905 — Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patie · not yet recruiting
- NCT07512219 — Comparison Between Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic Migraine · NA · not yet recruiting
- NCT07519694 — Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery · NA · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
- NCT07523386 — Compartive Study Between Cannulated Screw and Kws in Fixation of Distal Radius · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05853159 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sohag University
- Last refreshed: 10 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05853159.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing